


Bispecific T Cell Engager (BiTE) targeting pan-Tissue microenvironment marker CD155

CD155-targeting bispecific T-cell engager (BiTE) that crosslinks T-cells to CD155-expressing cells to exploit the immunosuppressive tumour tissue microenvironment into a therapeutic advantage.

CD155 BiTE is comprised of anti-CD155 scFv x anti-CD3 scFv, which crosslinks T-cells to CD155-expressing cells to form pseudoimmune synapses where clustering of CD3 triggers the release of cytotoxic granulates to kill the CD155 expressing cells.

Applications: Cancer immunotherapy, gene therapies, oncolytic virotherapies



Features	Benefits
Targets CD155, which is differentially expressed in the tissue microenvironment (TME)	Selective targeting of multiple cell types within TME in one go, but not healthy cells

Features	Benefits
Combines pan-TME marker CD155 with bispecific T cell engager	Allows exploitation of immunosuppressive nature of TME, depleting the TME from periphery to allow easier infiltration of immune cell and anti-cancer biologics into the tumour
Small size of BiTE	Prevents any on-target off-tumour effect, and rapid renal clearance if there is any entry to circulation
Stand alone or combination use	Use in combination with different gene therapies or oncolytic virotherapies

Awaiting patent and Available for

- Co-development
- Consulting
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided 'as is' without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.